Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, announce that they have amended and restated the merger agreement entered into by the parties on August 11, 2024, pursuant to which the companies will seek to merge the two organizations. Under the terms of the amended and restated merger agreement, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $3.10 per share in cash.
Read the full article: Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement //
Source: https://www.businesswire.com/news/home/20241209786407/en/Crown-Laboratories-and-Revance-Enter-into-Amended-and-Restated-Merger-Agreement